|
|
 |
FRANCE-INDIA-PHARMACEUTICAL-GILEAD-HEPATITIS-FILES
(FILES) In this photograph taken on April 29, 2014, members of the association Act Up hold signs in front of a stand of US pharmaceutical giant Gilead Sciences to denounce the high price of a new drug, Sofosbuvir, to treat Hepatitis C, in Montpellier, southern France. US biotechnology firm Gilead Sciences announced September 15 that it has signed generic licensing deals with seven India-based companies to increase access to its Hepatitis C drugs in the developing world. The non-exclusive agreements allow the companies to make the drug sofosbuvir, known as Sovaldi that is sold at the cost of $1,000 a tablet in the United States, for distribution in 91 developing countries, the company said in a statement. AFP PHOTO/SYLVAIN THOMAS/FILES
|
|
|
|
Detalii fotografie |
| Loc: |
|
Montpellier, Hérault, FRANCE |
|
| Sursa: |
|
AFP / Mediafax Foto |
|
| Fotograf: |
|
SYLVAIN THOMAS |
|
| Data: |
|
15 Septembrie 2014 |
|
| Dimensiuni: |
|
3800 x 2529 (1.22 MB) |
|
|
|
|
|
|